Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Dementia Guidelines topic
No spam. Unsubscribe anytime.
Collaborative flags uncertainty over blood‑based dementia biomarkers and pushes for specialty‑led use
Summary
Work‑group members warned that blood‑based biomarkers for dementia are creating referrals for people without symptoms; the Collaborative recommended limiting current use to specialty care and emphasized caregiver support, wraparound care and alignment with CMS GUIDE models.
Presenters to the Collaborative raised concerns that emerging blood‑based biomarkers for Alzheimer's and other dementias are being used in ways that can confuse patients and primary care clinicians. One presenter warned that family medicine providers sometimes refer patients with positive biomarker results "without cognitive symptoms and normal cognitive testing," creating a gap in guidance for primary care.
The work group recommended emphasizing specialty‑level use for most biomarkers until guidance is clearer and urged development of clear talking points for primary care clinicians who encounter patient‑initiated tests. Presenters also described draft guidance for post‑diagnosis care, stressing caregiver assessment and wraparound supports; they cited the CMS GUIDE model as an aspirational example for holistic, coordinated care. The Collaborative did not adopt a final policy at this meeting but will refine guidelines and resources, and announced a summit on October 23 in Yakima to share learning and tools.
Provenance: topicintro SEG 462; topfinish SEG 736
